Please login to the form below

Not currently logged in
Email:
Password:

BMS and Pfizer's Eliquis in trial success

Bristol-Myers Squibb and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation 

Bristol-Myers Squibb (BMS) and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation. 

In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, Eliquis met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism. 

The drug met the key secondary endpoints of superiority on efficacy and on International Society on Thrombosis and Hemostasis major bleeding compared to warfarin.

Eliquis, a new oral direct Factor Xa inhibitor, is being developed by the alliance of BMS and Pfizer.

The companies expect to submit regulatory filings in atrial fibrillation in the US and Europe in the third or fourth quarter of 2011.

The detailed results of the ARISTOTLE study will be presented on August 28 at the European Society of Cardiology Congress 2011 in Paris.

23rd June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics